◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksS › SANN

Santhera Pharmaceuticals Holding AG (SANN) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-16

Santhera Pharmaceuticals Holding AG (SANN) operates in the Biotechnology industry and is headquartered in Pratteln, Switzerland with about 93 employees. Its market capitalization is roughly CHF 242 million. In the fiscal year ended 2025-12-31, SANN reported CHF 77M in revenue and (CHF 49M) in net income.

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia.

Interactive charts & full statements →

SANN Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueCHF 77MCHF 39MCHF 103MCHF 8M
Gross ProfitCHF 15MCHF 24MCHF 100MCHF 4M
Operating Income (EBIT)(CHF 38M)(CHF 33M)CHF 51M(CHF 52M)
Net Income(CHF 49M)(CHF 42M)CHF 55M(CHF 71M)

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SANN Free Cash Flow History

SANN Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCHF 148MCHF 152MCHF 110MCHF 64M
Total LiabilitiesCHF 160MCHF 125MCHF 50MCHF 107M

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SANN viewer.

Other Companies in Biotechnology

← SANMAll “S” companiesSANO1 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.